1 active not recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
Follow Patient Preference: new trials by email Literature Review of Patient Preference trials Research Report on Patient Preference
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations relatlimab+nivolumab, relatlimab+nivolumab+rHuPH20, nivolumab - Melanoma | Phase 2 | Active not recruiting | Bristol-Myers Squibb | 100 | 2023-11-06 | 2026-09-14 |
Melanoma (1) · Neoplasm Metastasis (1)
Behavior (1) · Health Behavior (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Nerve Tissue (1) · Neoplastic Processes (1) · Neuroectodermal Tumors (1) · Neuroendocrine Tumors (1) · Nevi and Melanomas (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Patient Satisfaction (1) · Skin Diseases (1)
Chile (1) · Greece (1) · Italy (1) · Spain (1) · United States (1)
2023 (1)